Ticlopidine and Antiplatelet Therapy

  title={Ticlopidine and Antiplatelet Therapy},
  author={Patricia Flores-Runk and Ralph H. Raasch},
  journal={Annals of Pharmacotherapy},
  pages={1090 - 1098}
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of ticlopidine. Comparisons with other antiplatelet agents are presented, with an emphasis on efficacy, and a recommendation is provided regarding ticlopidine's place in therapy. DATA SOURCES: A MEDLINE literature retrieval of English-language journal articles from 1987 to January 1993 and references identified from bibliographies of review articles and clinical trials. STUDY SELECTION: Randomized, blind… 

Figures and Tables from this paper

Vasomodulatory action of clopidogrel and ticlopidine.
Platelet and Thrombin Inhibitors as Adjuncts to Thrombolytic Therapy and Percutaneous Coronary Interventions: A Review
The mechanisms of thrombus formation are described, the mechanism of action of available antithrombotic pharmacological agents are detailed, and recent clinical trials of these agents are reviewed.
Current Antiplatelet Therapy
A substantial portion of this chapter will review the preclinical and clinical development of this monoclonal antibody as antiplatelet therapy for the treatment of ischemic complications associated with percutaneous coronary revascularization.
Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats
A significant increase in the AUC of losartan (9 mg/kg) by ticlopidine could be attributed to the inhibition of CYP2C9- and 3A4-mediatedLosartan metabolism in small intestine and/or in liver.
Interaction between clarithromycin and oral anticoagulants
The addition of diphenhydramine into a vancomycin infusion to decrease phlebitis is reported, following previous success with hydrocortisone admixed with erythromycin to reduce phle Bitis.
Platelet aggregation and platelet‐derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: A randomized study comparing trapidil plus ticlopidine with heparin treatment
The study demonstrates that the incidence of type 2 stenosis of the transjugular shunt can be reduced by combined inhibition of platelet aggregation and PDGF activity.


The second case reported in the literature of the association of Ticlopidine and severe aplastic anaemia is described, where the coexistence in this last case of hypothyroidism confuses the possible role of the drug as a cause of marrow depression.
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
It is concluded that ticlopidine may well be used instead of anticoagulants for prevention of postoperative occlusion of aorto-coronary bypass grafts.
Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group.
The findings confirm the importance of platelets in the pathogenesis of unstable angina and the usefulness of antiplatelet treatment for the prevention of cardiovascular events.
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.
Evidence is provided of a beneficial effect of ticlopidine in both men and women with a recent thromboembolic stroke, and a smaller estimate of risk reduction for stroke, myocardial infarction, or vascular death is given.
The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial.
During the first two weeks after AMI significant changes in coagulation parameters and fibrinolysis indicated an increased risk of thrombosis in both groups, but these parameters were unaffected by the platelet inhibitory therapy.
"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.
It is concluded that, in patients comparable to those defined in the protocol, Aspirin (1 g) has a significantly beneficial effect in the secondary prevention of atherothrombotic cerebral infarction.
Antiplatelet therapy is effective in the prevention of stroke or death in women: subgroup analysis of the European stroke prevention study (ESPS)
In the relatively randomly selected patient population from one Finnish center, a combination of dipyridamole and acetylsalicylic acid is as effective in women as in men in the prevention of stroke or death.
Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin.
Platelet aggregation in response to all doses of ADP was depressed more by T than by ASA, and responses to adrenaline, and arachidonate were affected more by ASA than by T, while for all other agents, differences were not significant.